Blockchain Registration Transaction Record

SureNano Science's GEP-44 Targets Obesity Market with Novel Triple Agonist

SureNano Science (CSE: SURE) features in BioMedWire editorial highlighting its GEP-44 triple agonist for obesity and diabetes, offering improved tolerability and potential non-injectable delivery. Learn more about this next-gen GLP-1 therapy.

This news matters because obesity and metabolic diseases affect over 650 million adults worldwide, and current GLP-1 therapies often require injections and have tolerability issues. SureNano's GEP-44, a triple agonist with potential non-injectable delivery, could offer a more effective and convenient treatment option, improving patient compliance and outcomes. The company's shift from surfactant distribution to pharmaceutical development signals a strategic move into a high-growth market, making it a stock to watch for investors interested in biotech innovation.